poisar

Stock

Travere Therapeutics, Inc. TVTX

$55.89-2.43%

Overview

TVTX market data

Price History

TVTX price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.29
Diluted earnings per share over the trailing twelve months.
Beta
1.02
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$15.03 – $60.10
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $5.3K · P/B 29.77 · P/S 9.93.

Company News

10 captured
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $62Benzinga · Jul 30, 2026, 3:54 PM
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmGlobenewswire Inc · Jul 17, 2026, 11:15 AM
8-K filing — Travere Therapeutics, Inc. (TVTX)SEC EDGAR · Jul 9, 2026, 9:10 PM
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65Benzinga · Jun 25, 2026, 2:25 PM
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61Benzinga · Jun 22, 2026, 1:01 PM
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60Benzinga · Jun 18, 2026, 3:30 PM
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70Benzinga · Jun 15, 2026, 5:55 PM
Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65Benzinga · Jun 12, 2026, 1:45 PM
Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extension Of FILSPARI In Treatment Of Focal Segmental GlomerulosclerosisBenzinga · Jun 4, 2026, 2:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock